Diabetes MAYER B. DAVIDSON, MD,* CO-EDITOR-IN-CHIEF; HENRY N. GINSBERG, MD, REVIEWER; TERRENCE F. FAGAN, MANAGING EDITOR; CHING-LING CHEN, PhD, WRITER
|
|
- Belinda Strickland
- 5 years ago
- Views:
Transcription
1 Professional Postgraduate Services Release Date: March 14, 2008 Valid Through: July 14, 2008 Sponsor This educational activity is a component of the National Diabetes Education Initiative (NDEI ), sponsored by Professional Postgraduate Services (PPS). Clinicians who wish to receive CME credit for this educational activity should do the following: (1) read the current issue; and (2) complete the post-test and evaluation form included to conclude this CME activity. You may also complete the post-test and evaluation form on our website, To apply for CME credit, return the completed post-test and evaluation form to: Professional Postgraduate Services CME Dept. T Meadowlands Parkway Secaucus, NJ You may also fax the completed materials to 1 (201) If you have any questions, please call 1 (800) Ext Applicants will receive a certificate of participation from PPS by return mail within 6 to 8 weeks of the date of receipt of the completed evaluation form and post-test. Online applicants will automatically receive their CME credit certificate upon completion of the post-test and evaluation form. Target Audience This educational activity is designed for primary care physicians, internal medicine specialists, endocrinologists, diabetologists, cardiologists, and other healthcare professionals involved in the care and management of patients with type 2 diabetes, insulin resistance, and cardiovascular disease. Learning Objectives With information from the latest evidence-based studies, participants should be able to: Identify patients with insulin resistance, type 2 diabetes, and/or cardiovascular disease Select the most appropriate therapeutic regimen for patients with type 2 diabetes and its macrovascular and microvascular complications Identify risk factors for cardiovascular disease in patients with type 2 diabetes and select an appropriate therapeutic regimen Accreditation Professional Postgraduate Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Professional Postgraduate Services designates this educational activity for a maximum of.75 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity. AAFP credit Clinical Insights in Diabetes has been reviewed and is acceptable for up to 9 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 5/1/07. Term of approval is for one year from this date. This issue is approved for.75 Prescribed credit. Credit may be claimed for one year from the date of this issue. Grantor This CME activity is supported by an educational grant from Takeda Pharmaceuticals North America, Inc. Off-Label Disclosure Some of the drug treatments discussed in this issue may note uses not approved by the Food and Drug Administration. Articles containing such uses will be noted at the end of the article. Professional Postgraduate Services is a business unit of KnowledgePoint360 Group, LLC, Secaucus, NJ. CLINICAL INSIGHTS IN Diabetes MAYER B. DAVIDSON, MD,* CO-EDITOR-IN-CHIEF; HENRY N. GINSBERG, MD, REVIEWER; TERRENCE F. FAGAN, MANAGING EDITOR; CHING-LING CHEN, PhD, WRITER Sex-Specific General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study T he major risk factors for developing cardiovascular disease (CVD), including age, sex, high blood pressure, smoking, dyslipidemia, and diabetes status, often converge and interact multiplicatively to promote cardiovascular risk. CVD, as defined by the Framingham Heart Study, is a composite of coronary heart disease (CHD), cerebrovascular disease, peripheral vascular disease, and heart failure. Several validated risk prediction algorithms are commonly used for assessment of risk of specific components of CVD and for treatment of risk factors. Their use in primary care, however, is less frequent mainly because of the multiplicity of these prediction models, each algorithm predicting an individual CVD component. The purpose of the present study is to develop a single multivariable risk prediction tool incorporating all the risk factors for CVD that would enable primary care physicians to identify high-risk candidates for any and all initial atherosclerotic CVD events using measurements routinely available in the primary care setting. D Agostino and colleagues used Cox proportional-hazards regressions to evaluate the risk of developing a first CVD event during a maximum follow-up period of 12 years. Sex-specific multivariable risk functions, referred to as general CVD algorithms, were derived with incorporation of covariates, including age, total and highdensity lipoprotein cholesterol, systolic blood pressure, treatment for hypertension, smoking, and diabetes status. A total of 8,491 participants in the Framingham Heart Study (mean age, 49 years; 4,522 women) who attended a routine examination when aged between 30 and 74 years and were free of CVD events were included for evaluation of the performance of the newly developed sex-specific general CVD algorithms for predicting all and individual CVD events. Over 12 years of follow-up, 1,174 participants (456 women) developed a first CVD event. Highly statistically significant relations were observed between all risk factors evaluated and incident CVD, indicating that these risk factors predict CVD risk (multivariable-adjusted P<0.0001). The sex-specific general CVD VOLUME 11, NUMBER 2 FEBRUARY 2008 algorithms demonstrated good discrimination (C statistic, [men] and [women]) and calibration for predicting CVD risk. (See Tables, page 2.) An excellent goodness of fit was seen in the calibration plots by comparing model-based predicted risk and actual observed risk in men and women. The new CVD prediction models also performed better than the Framingham CHD risk functions in the prediction of CVD risk. Furthermore, the new general CVD risk formulation permits the prediction of the risk of individual CVD components by providing discrimination and calibration that are as good as those using individual disease-specific multivariable risk formulations. Simpler CVD risk prediction models were established from simple adjustments to the general CVD risk algorithms for estimation of the risks of each CVD component. Two such simple risk scores were presented: one based on all traditional risk factors, and the other based on nonlaboratory-based predictors. The simple office-based nonlaboratory CVD risk prediction function, which incorporated body mass index instead of laboratory measurements such as total and HDL cholesterol, performed reasonably well with good discrimination and calibration. The strength of the present study is the inclusion of a large community-based sample that is under continuous surveillance using the same standardized criteria for CVD events and the assessment of model performance measures with disease-specific profiles. Possible limitations of this study include transportability of the CVD risk function. D Agostino and associates concluded that a simple sex-specific multivariable risk factor algorithm can be conveniently used to assess general CVD risk as well as risk of individual CVD events in an office-based nonlaboratory, primary care office or clinic. Moreover, the estimated absolute CVD event rates can be used to identify risk and also to guide prevention of CVD events. D Agostino RB Sr et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation. 2008;117: * Dr Davidson is Director, Clinical Center of Research Excellence, at Charles R. Drew University, Los Angeles, California. He has indicated the following relevant financial relationships: consultant for Amgen Pharmaceuticals, Amylin Pharmaceuticals, and Daiichi Sankyo, Inc., and speakers bureau member with Amylin Pharmaceuticals, Eli Lilly and Company, and Merck & Co., Inc. Dr Ginsberg is the Irving Professor of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York. He has indicated the following relevant financial relationships: grant research support, Isis Pharmaceuticals, Inc., and Takeda Pharmaceuticals North America, Inc.; retained consultant, Merck & Co., Inc., Pfizer Inc., and Takeda Pharmaceuticals North America, Inc. PPS staff members Managing Editor Terrence F. Fagan, Senior Medical Writer Ching-Ling Chen, PhD, Program Director Jorge Mojena, and CME Program Manager Wadee ah Terry have indicated no relevant financial relationships.
2 CVD Points for Women Points Age, years HDL-C Total C SBP (un) SBP (t) -3 < < < < * 160+ *Over age 54, add 7 points, plus 1 point for Add 0 points for nonsmoker or without diabetes. every 5 additional years up to age 75+ years Add 3 points for smoker. (eg, 8 pts for 55 59, 9 pts for 60 64, etc.) Add 4 points for diabetes. Total C = total cholesterol. SBP = systolic blood pressure. (un) = untreated. (t) = treated. CVD Risk for Women* Total Points Risk % < >20 >30 *Risk % incrementally increases in each category. Adapted from RB D Agostino Sr et al. Circulation. 2008;117: Used with permission. CVD Points for Men Points Age, years HDL-C Total C SBP (un) SBP (t) < < < < * 160+ *Over age 44, add 6 points for 45 49, Add 0 points for nonsmoker or without diabetes. 8 pts for 50 54, 10 pts for 55 59, Add 3 points for diabetes. 11 pts for 60 64, 12 pts for 65 69, Add 4 points for smoker. 14 pts for 70 74, and 15 pts for 75+. Total C = total cholesterol. SBP = systolic blood pressure. (un) = untreated. (t) = treated. CVD Risk for Men* Total Points Risk % >30 *Risk % incrementally increases in each category. Adapted from RB D Agostino Sr et al. Circulation. 2008;117: Used with permission. 2
3 COMMENTARY HENRY N. GINSBERG, MD, Irving Professor of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York. The article by D Agostino et al provides a new algorithm for determining 10-year risk for all CVD based on baseline characteristics and follow-up of the combined original and offspring Framingham cohorts. By providing a means to assess risk for all CVD, which includes fatal and nonfatal myocardial infarction, stroke, peripheral vascular disease, and heart failure, the authors hope that practicing physicians, particularly internists and generalists, will achieve a more global sense of the risk of their patients. Of particular note is the demonstration that the new algorithm has equal predictive power when BMI is used instead of total cholesterol and HDL cholesterol; this would allow assessment of total CVD risk without the need for a blood sample and laboratory measurements. However, since the goal of quantitating CVD risk would be to intervene, a lipid profile would be required, as would some measure of glucose or A1C. Thus the utility of the laboratory-independent scoring system is not clear. It would be particularly useful if the algorithm automatically provided, in addition to overall CVD risk, individual risks for the components (CHD, stroke etc), particularly since the authors note that certain risk factors were more closely associated with particular component outcomes. The healthcare professional could then assess both global risk and individual CVD risks. Intensified Multifactorial Intervention Reduces Mortality in Type 2 Diabetes T ype 2 diabetes is known to be linked to a high rate of complications related to cardiovascular (CV) events, and a high rate of death, which is about twice as high as that among individuals without the disease. In the earlier Steno-2 study, a prospective, randomized, open-label trial, Gaede and colleagues demonstrated that intensified multifactorial intervention with the use of renin-angiotensin system blockers, aspirin, and lipid-lowering agents significantly reduced the risk of nonfatal cardiovascular disease (CVD) among patients with type 2 diabetes and microalbuminuria during the mean treatment period of 7.8 years. However, the effect of such intensive therapy on mortality in these patients was not clear. To address this question, Gaede and colleagues conducted the present follow-up study to evaluate whether the intensive therapy has any impact on the rate of death, and whether the reduction of CVD risk by the intensive therapy is maintained during the follow-up study. In the original Steno-2 study, 160 Danish patients with type 2 diabetes and persistent microalbuminuria were randomly selected to receive intensified multifactorial therapy or conventional therapy for an average period of 7.8 years. All patients in the intensive-therapy group received an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), regardless of blood pressure, for treatment of microalbuminuria, a low dose of aspirin, and a lipid-lowering medication such as a statin, in addition to dietary modification, increased activity, and antihyperglycemic medications. Defined targets for the intensive therapy group were based on current guidelines from the American Diabetes Association and included an A1C of <6.5%, blood pressure <130 mm Hg systolic and <80 mm Hg diastolic, fasting serum triglyceride level <150 mg/dl, and fasting serum total cholesterol level <175 mg/dl. Patients were subsequently followed for a mean of 5.5 years until December 31, There were no protocol-mediated differences during this follow-up. All subjects in the original 3 study had returned to their own doctors, and all were informed of that study s results, so treatments during follow-up were at the discretion of the patients and their physicians. The primary endpoint at 13.3 years of follow-up was the time to death from any cause, and the secondary endpoints were death from CV causes and a composite of CVD events. During the entire 13.3 years of study, 24 patients (30%) in the intensive-therapy group died, as compared with 40 patients (50%) in the conventional-therapy group (hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.32 to 0.89; P=0.02). The risk of death from CV causes was also lowered by multiple intensive intervention; 9 patients in the intensive-therapy group died from CV causes, as compared with 19 in the conventional-therapy group (HR, 0.43; 95% CI, 0.19 to 0.94; P=0.04). A total of 209 CV events occurred during the 13.3 years of observation; intensive therapy was associated with a lower risk of these events (HR, 0.41; 95% CI, 0.25 to 0.67; P<0.001). Furthermore, fewer diabetes-related diseases and major side effects were observed in the intensive-therapy group. For instance, only 1 patient in the intensive-therapy group had progression to end-stage renal disease, as compared with 6 patients in the conventionaltherapy group (P=0.04). In addition, fewer patients in the intensive-therapy group vs the conventional therapy group required retinal photocoagulation (relative risk, 0.45; 95% CI, 0.23 to 0.86; P=0.02). From the present study, the authors concluded that intensive intervention with multiple drug combinations and behavior modification to manage blood glucose, blood pressure, and cholesterol had sustained the beneficial effects on the reduction of the risk of CV events as well as the risk of mortality from any cause or from CV causes, and thus prolonged the lives of patients with type 2 diabetes. Gaede P et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:
4 Clinical Insights in Diabetes Post-Test February 2008 For a complete list of additional PPS educational activities log on to the following websites: 1) In a Cardiovascular Risk Profile algorithm devised by RB D Agostino Sr et al, 3 of the 4 factors below actually deduct points from the total risk score. Which does not? a. An untreated systolic blood pressure level below 120 mm Hg b. Patient is a nonsmoker c. A treated systolic blood pressure level below 120 mm Hg (women only) d. An HDL cholesterol level of 50 mg/dl or above 2) A follow-up to the Steno-2 trial of patients with type 2 diabetes compared the group that originally received intensive treatment with multiple drug therapy and behavior modification to the group that originally received conventional diabetes treatment. Which of the following results were observed in this study? a. Risk of death from all causes was significantly lower in the intensive treatment group b. Risk of death from cardiovascular (CV) causes was significantly lower in the intensive treatment group c. Risk of any CV events was significantly lower in the intensive treatment group d. Risk of microvascular complications was significantly lower in the intensive treatment group e. All of the above ANSWER KEY 1. b) Patient is a nonsmoker. Status as a nonsmoker added 0 points to a total risk score, but did not deduct points. 2. e) All of the above. Even years after the original study, an intensive treatment regimen was shown to significantly reduce macrovascular and microvascular complications as well as overall mortality in patients with type 2 diabetes. STARTING IN MARCH 2008: Register online at for NDEI s new CME/CE regional dinner meeting series presenting the latest information on diabetes treatment titled, Managing the Complexities of Type 2 Diabetes: A Road Map for Improving Patient Care A Case-Based, Interactive CME/CE Dinner Program For more information about upcoming NDEI CME and CE activities, visit us at or call 1 (800) , ext Visit for information on other CME or CE activities. Clinical Insights in Diabetes is co-edited by NDEI faculty members Mayer B. Davidson, MD, and Silvio E. Inzucchi, MD. Clinical Insights in Diabetes is available to you via . If you would like to receive future issues via , please visit us online at EM-T PHYCME
5 CME Activity Registration/Evaluation Form Participants who wish to obtain CME credit for this educational activity, please complete the contact information below, sign this form, and fax it with the completed post-test to 1 (201) or mail to: Professional Postgraduate Services, CME Dept. T196, 150 Meadowlands Parkway, Secaucus, NJ You may download previous issues of Clinical Insights in Diabetes e-newsletters by visiting us online at I have completed this activity as designed: (Signature) (Date) PLEASE PRINT CLEARLY: Dr Mr Mrs Ms Prof Other (Please specify) First Name Last Name Degree MD PharmD DO NP PA RPh Other (Please specify) Specialty Primary Care Internal Medicine Endocrinology Cardiology Other Profession Activity Code: T Issue Date: March 14, 2008 CME Credit Availability: Through July 14, 2008 PREFERRED MAILING ADDRESS Home Office Practice Academic Dept/Div/Suite/Unit/Affil Street City/State/ZIP Code Country (Please print clearly) Phone: - - Fax: - - Overall Program 1. The activity met the stated objectives in such a way that I am better able to: Strongly Disagree Disagree Agree Strongly Agree a. Identify patients with insulin resistance, type 2 diabetes, and/or cardiovascular disease b. Select the most appropriate therapeutic regimen for patients with type 2 diabetes and its macrovascular and microvascular complications c. Identify risk factors for cardiovascular disease in patients with type 2 diabetes and select an appropriate therapeutic regimen 2. Overall, the activity was presented in a fair-balanced manner. Yes No* * If you checked No, please explain. 3. Overall, the activity was free from commercial bias. Yes No* * If you checked No, please explain. 4. In reflecting on your practice, what type of impact will this educational activity have? This program has validated my practice in the treatment of type 2 diabetes and its cardiovascular complications. Need more information before making a change. (Please specify what information you would require.) 5. What is the largest challenge or unmet educational need in your practice? 6. What other clinical issues are you and your colleagues challenged by that could be addressed in a CME activity? (Please specify.) Thank you for your participation. EM-T PHYCME
Mortality Rates Reduced in Men but Not in Women With Diabetes, 1971 to 2000
P r o f e s s i o n a l P o s t g r a d u a t e S e r v i c e s Release Date: September 2007 Valid Until: January 2008 Sponsor his educational activity is a component of the National Diabetes Education
More informationDiabetes. Diabetic Retinopathy and the Risk of Coronary Heart Disease: The ARIC Study C L I N I C A L I N S I G H T S I N
P r o f e s s i o n a l P o s t g r a d u a t e S e r v i c e s Release Date: August 2007 Valid Until: December 2007 Sponsor This educational activity is a component of the National Diabetes Education
More information... CME/CPE QUIZ... CME/CPE QUESTIONS
CME/CPE QUESTIONS Continuing Medical Education Accreditation The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 credit hours in category 1 credit toward
More informationHealthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice
CONTINUING EDUCATION Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice GOAL To provide participants with current information about current blood pressure goals and effective
More informationCME/CE QUIZ CME/CE QUESTIONS
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation The University of Cincinnati College of Medicine designates this educational activity for a maximum of two (2) AMA PRA Category 1
More informationReduced Carbohydrate Intake May Lower Cardiovascular Risk CME
To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/516977 This activity is supported by funding from WebMD. Reduced
More informationDiabetes: A Cardiovascular Disease Current Approaches to Treatment A Continuing Education Program
Diabetes: A Cardiovascular Disease Current Approaches to Treatment A Continuing Education Program Sponsored by: Blue Cross and Blue Shield of New Mexico and New Mexico Health Care Takes On Diabetes Objectives:
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationA Clinical Context Report
Type 2 Diabetes in Practice An Expert Commentary with Silvio E. Inzucchi, MD A Clinical Context Report Clinical Context: Type 2 Diabetes in Practice Expert Commentary Jointly Sponsored by: and Clinical
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationThe Arthur C. Nielsen, Jr. Vascular Symposium: A Clinical Update on Vascular Medicine and Surgery
The Arthur C. Nielsen, Jr. Vascular Symposium: A Clinical Update on Vascular Medicine and Surgery Chicago, Illinois March 7, 2014 Sponsored by: of GENERAL INFORMATION The s Center for Vascular Disease
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationManagement of Atrial Fibrillation in Friday, October 6, 2017 Seattle
virginia mason continuing medical education Friday, October 6, 2017 Seattle Faculty course directors: Christopher L. Fellows, MD, FACC, FHRS Section Head, Cardiology Robert W. Rho, MD, FACC, FHRS J. Susie
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationFINAL ENDURING OUTCOMES REPORT
FINAL ENDURING OUTCOMES REPORT OVERVIEW This report summarizes consolidated outcomes data from an enduring satellite symposium activity that was launched In March 2017 and ran for 12 months, cumulatively,
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationSafety of Anacetrapib in Patients with or
Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationA Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationCardiovascular Update for the Primary Care Provider. Friday, June 12, 2015 Seattle
virginia mason continuing medical education Cardiovascular Update for the Primary Care Provider Friday, June 12, 2015 Seattle Faculty course director: J. Susie Woo, MD, FACC The Heart Institute at Virginia
More informationType 1 Diabetes: New and Emerging Therapeutic Strategies to Address Unmet Needs
A CME REGIONAL MEETING SERIES Type 1 Diabetes: New and Emerging Therapeutic Strategies to Address Unmet Needs Thursday, March 7, 2019 Halekulani Hotel Honolulu, Hawaii THIS ACTIVITY IS JOINTLY PROVIDED
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationWOMEN S HEALTH FOR PRIMARY CARE. San Diego, California Hotel del Coronado August 10 13, 2017
WOMEN S HEALTH FOR PRIMARY CARE San Diego, California Hotel del Coronado August 10 13, 2017 Thursday, August 10th: 7:30 am 8:00 am Registration and Hot Breakfast 8:00 am 9:00 am Gynecology Abnormal Uterine
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationModelling Reduction of Coronary Heart Disease Risk among people with Diabetes
Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationThe ACCELERATE Trial
The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More information... CPE/CNE QUIZ... CPE/CNE QUESTIONS
CPE/CNE QUESTIONS Continuing Pharmacy Education Accreditation The Virginia Council on Pharmaceutical Education is approved by the American Council on Pharmaceutical Education as a provider of continuing
More informationDIABETES UPDATE and ADVANCES IN ENDOCRINOLOGY AND METABOLISM
Divisions of Endocrinology and Metabolism Department of Medicine University of California, San Francisco School of Medicine DIABETES UPDATE and ADVANCES IN ENDOCRINOLOGY AND METABOLISM Thursday - Saturday,
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationType 2 Diabetes in Practice. An Expert Commentary with Farhad Zangeneh, MD, FACP, FACE A Clinical Context Report
Type 2 Diabetes in Practice An Expert Commentary with Farhad Zangeneh, MD, FACP, FACE A Clinical Context Report Clinical Context: Type 2 Diabetes in Practice Expert Commentary Jointly Sponsored by: and
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationNotes Indicate to the group that this patient will be the focus of today s case discussion.
1 Indicate to the group that this patient will be the focus of today s case discussion. Read out the case authors and their disclosure information. Instructions Fill out prior to the meeting and disclose
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationHeart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial
Heart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial Sripal Bangalore, MD, MHA, Chuan-Chuan Wun, PhD, David A DeMicco, PharmD,
More informationChronic Benefit Application Form Cardiovascular Disease and Diabetes
Chronic Benefit Application Form Cardiovascular Disease and Diabetes 19 West Street, Houghton, South Africa, 2198 Postnet Suite 411, Private Bag X1, Melrose Arch, 2076 Tel: +27 (11) 715 3000 Fax: +27 (11)
More informationEuroPrevent 2010 Fatal versus total events in risk assessment models
EuroPrevent 2010 Fatal versus total events in risk assessment models Pekka Jousilahti, MD, PhD,Research Professor National Institute for Health and Welfare, Finland Risk assessment models Estimates the
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More information20th Annual Conference. Frontiers in Diabetes Research: Biological Bases for Complications of Diabetes
20th Annual Conference Frontiers in Diabetes Research: Biological Bases for Complications of Diabetes Saturday, November 17, 2018 Course Directors Domenico Accili, M.D., Russell Berrie Foundation Professor
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationPrevention of HIV-related Cardiovascular Disease: an enewsletter Series
Prevention of HIV-related Cardiovascular Disease: an enewsletter Series Final Outcomes Report Gilead Grant ID: ZZ03-16 Data reflective through October 6, 2017 Series Landing Page Overview Activity: enewsletter
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationDIABETES MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More information2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationENDOCRINOLOGY FOR PRIMARY CARE: Hilton Head Island, South Carolina Hilton Head Marriott Resort & Spa August 9 12, 2018
ENDOCRINOLOGY FOR PRIMARY CARE: Hilton Head Island, South Carolina Hilton Head Marriott Resort & Spa August 9 12, 2018 Thursday, August 9th: 7:00 am 7:30 am Registration and Hot Breakfast 7:30 am 8:30
More informationVal-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp
Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationNew Cardiovascular Horizons. Tucson. Multidisciplinary Strategies for Optimal Cardiovascular Care. Arizona February 7, 2015
New Cardiovascular Horizons Tucson Multidisciplinary Strategies for Optimal Cardiovascular Care Arizona February 7, 2015 Chairmen: Miguel Montero-Baker, Salvatore J. Tirrito, Craig M. Walker, Course Directors:
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationDIABETES and CANCER 2017:
Symposium on DIABETES and CANCER 2017: Novel Links and Treatments Friday, April 7, 2017 New York Academy of Medicine 1216 Fifth Avenue (at 103rd Street) 10029 Course Directors Professor of Medicine, Interim
More informationHealth Delivery and Technology in Today s DIABETES CARE
Health Delivery and Technology in Today s DIABETES CARE Applying Evidence Based Treatments to Personalized Care The Inn at St. John s. Plymouth, MI The 2018 Diabetes Care conference is sponsored by Grand
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationCARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE. Yosemite, California Tenaya Lodge at Yosemite September 21 23, 2018
CARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE Yosemite, California Tenaya Lodge at Yosemite September 21 23, 2018 Friday, September 21st: 7:00 am 7:30 am Registration and Hot Breakfast 7:30 am 8:30 am Cardiology
More informationMaking the Connection Between Patients and Providers
Making the Connection Between Patients and Providers A Comprehensive Overview of the Modern Treatment Strategies For People With Type 1 and Type 2 Diabetes Saturday, April 27, 2019 Hawaii Convention Center
More informationCARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE. Asheville, North Carolina The Omni Grove Park Inn May 18 20, 2018
CARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE Asheville, North Carolina The Omni Grove Park Inn May 18 20, 2018 Friday, May 18th: 7:30 am - 8:00 am Registration and Hot Breakfast 8:00 am - 9:00 am Pulmonary
More informationENDOCRINOLOGY FOR PRIMARY CARE
ENDOCRINOLOGY FOR PRIMARY CARE Las Vegas, Nevada The Cosmopolitan February 27 March 1, 2015 Participating Faculty Gregory A. Brent, MD Professor, Departments of Medicine and Physiology David Geffen School
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationBlood Pressure LIMBO How Low To Go?
Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity
More informationMeasure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner
2011 EHR Measure Specifications The specifications listed in this document have been updated to reflect clinical practice guidelines and applicable health informatics standards that are the most current
More informationCardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationPRI-MED UPDATES Long Beach, CA October 10-11, 2008 PROGRAM DIRECTORY
PRI-MED UPDATES Long Beach, CA October 10-11, 2008 PROGRAM DIRECTORY Accreditation Information Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME), which
More informationEarning, redeeming and merging CME/CE/CPD credit
UpToDate Earning, redeeming and merging CME/CE/CPD credit A step-by-step guide for clinicians accessing UpToDate through an EHR, clinician portal or other secure clinical system GET STARTED EARNING CME/CE/CPD
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More information